Dynamic Technology Lab Private Ltd Makes New $37,000 Investment in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Dynamic Technology Lab Private Ltd purchased a new position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) in the 3rd quarter, HoldingsChannel.com reports. The firm purchased 11,178 shares of the company’s stock, valued at approximately $37,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. BML Capital Management LLC boosted its position in shares of Atea Pharmaceuticals by 4.3% during the third quarter. BML Capital Management LLC now owns 6,650,000 shares of the company’s stock worth $22,278,000 after buying an additional 274,379 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Atea Pharmaceuticals by 55.2% during the second quarter. Dimensional Fund Advisors LP now owns 594,360 shares of the company’s stock worth $1,968,000 after buying an additional 211,428 shares during the period. Marshall Wace LLP purchased a new position in shares of Atea Pharmaceuticals during the second quarter worth $603,000. Almitas Capital LLC purchased a new position in shares of Atea Pharmaceuticals during the second quarter worth $4,271,000. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Atea Pharmaceuticals by 21.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 67,137 shares of the company’s stock worth $272,000 after buying an additional 11,968 shares during the period. 86.67% of the stock is currently owned by hedge funds and other institutional investors.

Atea Pharmaceuticals Trading Down 0.6 %

NASDAQ:AVIR opened at $3.48 on Wednesday. The stock has a fifty day moving average price of $3.41 and a 200 day moving average price of $3.56. Atea Pharmaceuticals, Inc. has a 12-month low of $2.88 and a 12-month high of $4.60.

Atea Pharmaceuticals (NASDAQ:AVIR) last released its earnings results on Thursday, November 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.13. During the same period in the previous year, the business earned ($0.40) earnings per share. As a group, sell-side analysts forecast that Atea Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Insider Buying and Selling at Atea Pharmaceuticals

In other Atea Pharmaceuticals news, CEO Jean-Pierre Sommadossi sold 33,941 shares of the firm’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $4.05, for a total value of $137,461.05. Following the sale, the chief executive officer now directly owns 5,890,053 shares in the company, valued at $23,854,714.65. This trade represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 17.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on AVIR. William Blair upgraded Atea Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Morgan Stanley upgraded Atea Pharmaceuticals from an “underweight” rating to an “equal weight” rating and lifted their target price for the company from $2.00 to $6.88 in a report on Tuesday, August 13th.

Atea Pharmaceuticals Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.